BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

.decimal, Inc. Gains 510k Clearance from the FDA to Market its p.d(TM) Software for Bolus Electron Conformal Therapy in the United States


5/12/2009 8:25:34 AM

SANFORD, Fla., May 11 /PRNewswire/ -- .decimal, leading manufacturer of patient-specific medical devices, gains 510k clearance to release the software necessary for the delivery of Bolus Electron Conformal Therapy (Bolus ECT(TM)), an advanced form of patient-specific electron therapy. Treating with bolus ECT will be available to users of all three of the major treatment planning systems: CMS XiO(TM), Varian Eclipse(TM) and Philips Pinnacle3(TM).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090203/CLTU104LOGO )

510k clearance to market the device makes it possible for cancer treatment centers in the United States to begin ordering, installing and using .decimal's propriety software, p.d, for bolus ECT. "We are now actively marketing bolus electron conformal therapy, and the response from institutions across the United States has been overwhelming as they begin to see the value to their patients through this innovative technology," says Mark Mills, Senior Vice President of Sales and Marketing at .decimal.

.decimal is the sole manufacturer of the bolus, as well as the sole software provider for bolus ECT planning.

Richard Sweat, President and CEO of the company explains, "The commercial availability of bolus electron conformal therapy is another example of our commitment to providing our customers with innovative treatment solutions and their patients with the best individualized electron treatment available in the world."

Bolus ECT can create favorable dose distributions for certain tumors of the chest wall, breast or head and neck, when a tumor volume has spread out near the patient surface and rendered other treatment problematic for a variety of reasons. Bolus ECT was first used at the University of Texas M.D. Anderson Cancer Center over ten years ago, but did not become commercially available until this software release.

"With this product we are enabling the 80% of radiation oncology facilities in the United States treating with electrons the opportunity to enhance their current electron delivery capabilities through our unique pay-as-you-go, Internet-based manufacturing business model," says Sweat.

.decimal is a medical device manufacturer of patient-specific devices, including missing tissue compensators, modulators for advanced IMRT delivery, bolus compensators for bolus electron conformal therapy, as well as apertures and range compensators used in proton therapy. The company has been providing radiation therapy products for over twenty years. For more information concerning .decimal, please see its Web site at www.dotdecimal.com.

CONTACT: Andrea Andrus, .decimal, 800-255-1613

Web site: http://www.dotdecimal.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES